Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mojca Skoberne is active.

Publication


Featured researches published by Mojca Skoberne.


Journal of Clinical Investigation | 2005

Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor–viral RNA interactions

Anne-Sophie Beignon; Kelli McKenna; Mojca Skoberne; Olivier Manches; Ida Dasilva; Daniel G. Kavanagh; Marie Larsson; Robert J. Gorelick; Jeffrey D. Lifson; Nina Bhardwaj

HIV-1 directly activates human plasmacytoid DCs (pDCs) by upregulating the expression of costimulatory and MHC molecules and maturation markers, increasing T cell stimulatory activity, and inducing the production of type I interferons and TNF-alpha. A consequence of this activation is the bystander maturation of myeloid DCs and overall enhancement of antigen-presenting function. However, little is known about the mechanism(s) of pDC activation by HIV-1. Here we demonstrate by in vitro studies that IFN-alpha production by pDC in response to HIV-1 requires at least 2 interactions between the cell and virus. Initially, envelope-CD4 interactions mediate endocytosis of HIV-1, as demonstrated through the use of inhibitors of binding, fusion, endocytosis, and endosomal acidification. Subsequently, endosomally delivered viral nucleic acids, particularly RNA, stimulate pDCs through TLRs, as activation is reproduced with purified genomic RNA but not viral RNA packaging-deficient HIV-1 and blocked with different inhibitory TLR ligands. Finally, by using genetic complementation, we show that TLR7 is the likely primary target. Viral RNA rather than DNA in early retrotranscripts appears to be the active factor in HIV-1 that induces IFN-alpha secretion by pDCs. Since the decline in pDCs in chronic HIV-1 infection is associated with high viral loads and opportunistic infections, exploiting this natural adjuvant activity of HIV-1 RNA might be useful in the development of vaccines for the prevention of AIDS.


Current Topics in Microbiology and Immunology | 2005

Apoptotic cells at the crossroads of tolerance and immunity.

Mojca Skoberne; Anne-Sophie Beignon; Marie Larsson; Nina Bhardwaj

Clearance of apoptotic cells by phagocytes can result in either anti-inflammatory and immunosuppressive effects or prostimulatory consequences through presentation of cell-associated antigens to T cells. The differences in outcome are due to the conditions under which apoptosis is induced, the type of phagocytic cell, the nature of the receptors involved in apoptotic cell capture, and the milieu in which phagocytosis of apoptotic cells takes place. Preferential ligation of specific receptors on professional antigen-presenting cells (dendritic cells) has been proposed to induce potentially tolerogenic signals. On the other hand, dendritic cells can efficiently process and present antigens from pathogen-infected apoptotic cells to T cells. In this review, we discuss how apoptotic cells manipulate immunity through interactions with dendritic cells.


Journal of Clinical Investigation | 2008

KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity

Mojca Skoberne; Alice Yewdall; Keith S. Bahjat; Emmanuelle Godefroy; Peter Lauer; Edward E. Lemmens; Weiqun Liu; Will Luckett; Meredith Leong; Thomas W. Dubensky; Dirk G. Brockstedt; Nina Bhardwaj

Vaccine strategies that utilize human DCs to enhance antitumor immunity have yet to realize their full potential. Approaches that optimally target a spectrum of antigens to DCs are urgently needed. Here we report the development of a platform for loading DCs with antigen. It is based on killed but metabolically active (KBMA) recombinant Listeria monocytogenes and facilitates both antigen delivery and maturation of human DCs. Highly attenuated KBMA L. monocytogenes were engineered to express an epitope of the melanoma-associated antigen MelanA/Mart-1 that is recognized by human CD8+ T cells when presented by the MHC class I molecule HLA-A*0201. The engineered KBMA L. monocytogenes induced human DC upregulation of costimulatory molecules and secretion of pro-Th1 cytokines and type I interferons, leading to effective priming of Mart-1-specific human CD8+ T cells and lysis of patient-derived melanoma cells. KBMA L. monocytogenes expressing full-length NY-ESO-1 protein, another melanoma-associated antigen, delivered the antigen for presentation by MHC class I and class II molecules independent of the MHC haplotype of the DC donor. A mouse therapeutic tumor model was used to show that KBMA L. monocytogenes efficiently targeted APCs in vivo to induce protective antitumor responses. Together, our data demonstrate that KBMA L. monocytogenes may be a powerful platform that can both deliver recombinant antigen to DCs for presentation and provide a potent DC-maturation stimulus, making it a potential cancer vaccine candidate.


Journal of Clinical Oncology | 2008

Use of KBMA Listeria monocytogenes as an antigen loading platform for dendritic cell-mediated induction of antitumor immunity

Mojca Skoberne; Alice Yewdall; Keith S. Bahjat; Edward E. Lemmens; Weiqun Liu; Peter Lauer; W. Luckett; Thomas W. Dubensky; Dirk G. Brockstedt; Nina Bhardwaj

3044 Background: Melanoma is one of the most rapidly growing cancers worldwide yet there is no satisfactory treatment. Dendritic cells (DC) are attractive cellular adjuvants which can increase host resistance to tumor. To optimally prime naive T cells, DCs must not only present high levels of MHC-peptide complexes, but must also undergo activation and maturation. Methods: The highly attenuated killed but metabolically active (KBMA) Listeria monocytogenes (Lm) were engineered to express the HLA-A*0201 CD8+ T cell epitopes of melanoma-associated antigen (MAA) MelanA/Mart-1 and of control influenza matrix protein, both encoded within the OVA scaffold protein. These bacteria served as a DC antigen-loading platform. Monocyte-derived DC were generated from PBMCs of healthy donors, infected with recombinant attenuated KBMA Lm (rLm) and evaluated for maturation and presentation of the tumor-specific epitope. These DC were also used to generate tumor-specific CD8+ T cell lines, which were tested for effector poten...


Trends in Molecular Medicine | 2004

Danger signals: a time and space continuum

Mojca Skoberne; Anne-Sophie Beignon; Nina Bhardwaj


Blood | 2006

The apoptotic-cell receptor CR3, but not αvβ5, is a regulator of human dendritic-cell immunostimulatory function

Mojca Skoberne; Selin Somersan; Wanda Almodovar; Tuan Truong; Kseniya Petrova; Peter M. Henson; Nina Bhardwaj


Nature Immunology | 2003

Type I interferons promote cross-priming: more functions for old cytokines

Anne-Sophie Beignon; Mojca Skoberne; Nina Bhardwaj


Blood | 2004

Killed but Metabolically Active Recombinant Listeria monocytogenes as an Antigen Delivery and Activation Platform for Human Dendritic Cell-Based Cancer Immunotherapy.

Dirk G. Brockstedt; Mojca Skoberne; Alice Yewdall; Keith S. Bahjat; Larry Corash; Thomas W. Dubensky; Nina Bhardwaj


Archive | 2013

dendritic cell immunostimulatory function 5, is a regulator of human β v α The apoptotic cell receptor CR3, but not

Nina Bhardwaj; Mojca Skoberne; Selin Somersan; Wanda Almodovar; Tuan Truong; Kseniya Petrova; Peter M. Henson


Archive | 2010

human dendritic-cell immunostimulatory function The apoptotic-cell receptor CR3, but not {alpha}vbeta5, is a regulator of

Nina Bhardwaj; Mojca Skoberne; Selin Somersan; Wanda Almodovar; Tuan Truong; Kseniya Petrova

Collaboration


Dive into the Mojca Skoberne's collaboration.

Top Co-Authors

Avatar

Nina Bhardwaj

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Keith S. Bahjat

Providence Portland Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge